Prelude Therapeutics Incorporated (PRLD)
NASDAQ: PRLD · Real-Time Price · USD
1.040
-0.120 (-10.34%)
At close: Sep 17, 2025, 4:00 PM EDT
1.040
0.00 (-0.03%)
After-hours: Sep 17, 2025, 7:54 PM EDT
Prelude Therapeutics Market Cap
Prelude Therapeutics has a market cap or net worth of $58.86 million as of September 17, 2025. Its market cap has decreased by -79.43% in one year.
Market Cap
58.86M
Enterprise Value
5.26M
1-Year Change
-79.43%
Ranking
Category
Stock Price
$1.04
Market Cap Chart
Since the IPO on September 25, 2020, Prelude Therapeutics's market cap has decreased from $806.64M to $58.86M, a decrease of -92.70%. That is a compound annual growth rate of -40.89%.
Market Cap History
| Date | Market Cap | % Change |
|---|---|---|
| Sep 16, 2025 | 65.66M | -6.43% |
| Dec 31, 2024 | 70.17M | -73.80% |
| Dec 29, 2023 | 267.79M | -6.83% |
| Dec 30, 2022 | 287.43M | -50.22% |
| Dec 31, 2021 | 577.35M | -80.97% |
| Dec 31, 2020 | 3.03B | 276.02% |
| Sep 25, 2020 | 806.64M | - |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| Eli Lilly and Company | 671.68B |
| Johnson & Johnson | 427.24B |
| AbbVie | 384.42B |
| UnitedHealth Group | 315.07B |
| Novo Nordisk | 248.69B |
| AstraZeneca | 240.71B |
| Novartis AG | 238.00B |
| Abbott Laboratories | 228.57B |